CAS: 5625-67-2; Piperazin-2-One

相似化合物

13754-41-1 76003-29-7 78818-15-2

上下游产品

CAS号105-39-5 氯乙酸乙酯 | CAS号107-15-3 乙二胺 | CAS号109-89-7 二乙胺 | CAS号24123-13-5 N-(2-氨基乙基)甘氨酸乙酯 | CAS号623-73-4 重氮乙酸乙酯 | CAS号1247428-43-8 N-(2-氨基乙基)-2-氯乙酰胺 | CAS号79-07-2 氯乙酰胺 | CAS号64-17-5 乙醇 | CAS号50-00-0 甲醛 | CAS号109384-26-1 4-甲基-3-氧代哌嗪-1-羧酸叔丁酯 | CAS号34770-60-0 1-甲基-3-氧代哌嗪 | CAS号780753-89-1 1-(4-氟苯基)-2-哌嗪酮 | CAS号78818-15-2 3-氧哌嗪-1-甲酸苯甲酯 | CAS号76003-29-7 3-氧代-1-哌嗪羧酸叔丁酯 | CAS号74011-42-0 4-氧诺氟沙星 | CAS号13754-41-1 4-苄基哌嗪-2-酮 | CAS号103237-52-1 氧丙沙星 | CAS号24123-14-6 N-(2-氨基乙基)甘氨酸 | CAS号177-11-7 4-哌啶酮缩乙二醇

N-(2-氨基乙基)甘氨酸乙酯 以 N,N-二甲基甲酰胺 作为反应溶剂,化学反应生成 2-哌嗪酮
参考文献:1-[2-(二苯基甲氧基)乙基]-和1-[2-[双[4-(4-氟苯基)甲氧基]乙基]-4-(3-苯基丙基)新型非哌嗪类似物的设计,合成和生物学评估哌嗪作为多巴胺转运蛋白抑制剂.
标题:1-[2-(二苯基甲氧基)乙基]-和1-[2-[双[4-(4-氟苯基)甲氧基]乙基]-4-(3-苯基丙基)新型非哌嗪类似物的设计,合成和生物学评估哌嗪作为多巴胺转运蛋白抑制剂.
摘要:合成了一系列新型的n-[2-(双芳基甲氧基)乙基]-N'-(苯丙基)哌嗪二胺,胺-酰胺和哌嗪酮类似物gbr 12909和12935,并将其评估为突触前单胺神经递质转运蛋白的抑制剂.该研究的主要目的是确定配体结合的选择性和抑制神经递质再摄取的能力的结构要求.通常,目标化合物保留了转运蛋白的亲和力.然而,结构变化对再摄取抑制和转运蛋白选择性产生了显着影响.例如,通过用n,N'-二甲基丙基二胺部分代替gbr结构中的哌嗪环而制备的类似物在去甲肾上腺素(ne)转运蛋白位点(例如4和5)显示出增强的结合和再摄取抑制选择性.其中酰胺氮原子连接到gbr分子的芳烷基部分的同类物显示出中等的亲和力(k(i)= 51-61 Nm)和对多巴胺转运蛋白(dat)位点的选择性.相反,与哌嗪环的任一氮原子(例如25和27)相邻的羰基的引入不能很好地耐受.从制备的化合物中,选择类似物16用于进一步评估.使用该同类物,可卡因以20
DOI:10.1021/jm990161H

专利信息

专利号:US-7825244-B2
优先权日:2005-06-10
标题:Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
发明人：BAINDUR NAND; GAUL MICHAEL DAVID; KREUTTER KEVIN DOUGLAS; XU GUOZHANG
权利人:JANSSEN PHARMACEUTICA NV
摘要:The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: n nwherein R 1 , R 2 , R 99 , and X are as defined herein, the use of such compounds in the synthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

专利号:US-5877278-A
优先权日:1992-09-24
标题:Synthesis of N-substituted oligomers
发明人：ZUCKERMANN RONALD N; GOFF DANE A; NG SIMON; SPEAR KERRY; SCOTT BARBARA O; SIGMUND AARON C; GOLDSMITH RICHARD A; MARLOWE CHARLES K; PEI YAZHONG; RICHTER LUTZ; SIMON REYNA
权利人:CHIRON CORP
摘要:A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a solid support-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability. Combinatorial libraries of cyclic compounds are disclosed wherein the cyclic compounds are comprised of at least one ring structure derived from cyclization of a peptoid backbone. The diversity of product compounds is generated by the sequential addition of substituted submonomers. The combinatorial library includes 10 or more, preferably 100 or more, and more preferably 1,000 or more distinct and different compounds. The library includes each of the product compounds in retrievable and analyzable amounts and preferably includes at least one biologically active compound. Methods of synthesizing the combinatorial libraries and assay devices produced using the libraries are disclosed as is methodology for screening for and obtaining biologically active cyclic organic compounds.

专利号:WO-2023102600-A1
优先权日:2021-12-06
标题:Synthesis of amphiphilic block copolymers and polymeric nanofibers produced therefrom
发明人：ZETTERLUND PER B; ISHIZUKA FUMI; KIM HYUN JIN; CHATANI SHUNSUKE; NIINO HIROSHI
权利人:NEWSOUTH INNOVATIONS PTY LTD
摘要:The present disclosure relates to the field of synthesis of block copolymers, and polymeric nanofibers having a core-shell morphology produced therefrom. The present disclosure relates to the field of synthesis of block copolymers where one block is more hydrophobic than the other block and is a different composition. The disclosure also relates to uses of these polymeric nanofibers in various applications, such as reinforcing a polymeric matrix and for coatings applications.

专利号:US-5569762-A
优先权日:1994-01-14
标题:Asymmetric synthesis of intermediates for retroviral protease inhibitor compounds
发明人：WISSNER ALLAN; TROVA MICHAEL P
权利人:AMERICAN CYANAMID CO
摘要:The disclosure describes an improved process for producing optically active compounds of Formula II or III, which compounds are useful as intermediates for preparing compounds active as inhibitors of retroviral protease enzymes: ##STR1## wherein R 1 , R 50 and Z are described in the specification. The improved process includes either synthesis of diastereomeric iodolactones which are separated prior to conversion to compounds of Formula II or III or synthesis of an epoxide which is converted directly to compounds of Formula II and III.

专利号:US-10787458-B2
优先权日:2014-09-25
标 题:Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines
发明人：HOVEYDA HAMID; DUTHEUIL GUILLAUME
权利人:OGEDA SA
摘要:Disclosed is a novel chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines of Formula (I): n nor a solvate thereof. The novel chiral synthesis avoids the use of protection/deprotection steps.

专利号:US-10918627-B2
优先权日:2016-05-11
标 题:Convergent and enantioselective total synthesis of Communesin analogs
发明人：MOVASSAGHI MOHAMMAD; LATHROP STEPHEN PAUL; POMPEO MATTHEW W; CHANG WEN-TAU TIMOTHY
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I): n nor a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R 1 -R 8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function.